RT Journal Article
T1 Lupinus angustifolius Protein Hydrolysates Reduce Abdominal Adiposity and Ameliorate Metabolic Associated Fatty Liver Disease (MAFLD) in Western Diet Fed-ApoE-/- Mice.
A1 Santos-Sánchez, Guillermo
A1 Cruz-Chamorro, Ivan
A1 Álvarez-Ríos, Ana Isabel
A1 Fernández-Santos, José María
A1 Vázquez-Román, María Victoria
A1 Rodríguez-Ortiz, Beatriz
A1 Álvarez-Sánchez, Nuria
A1 Álvarez-López, Ana Isabel
A1 Millán-Linares, María Del Carmen
A1 Millán, Francisco
A1 Pedroche, Justo
A1 Fernández-Pachón, María Soledad
A1 Lardone, Patricia Judith
A1 Guerrero, Juan Miguel
A1 Bejarano, Ignacio
A1 Carrillo-Vico, Antonio
K1 LDL
K1 NAFLD
K1 adipose tissue
K1 bioactive peptides
K1 cholesterol
K1 inflammation
K1 lupin
K1 oxidative stress
K1 steatosis
AB Metabolic-associated fatty liver disease (MAFLD) is the most important cause of liver disease worldwide. It is characterized by the accumulation of fat in the liver and is closely associated with abdominal obesity. In addition, oxidative stress and inflammation are significant features involved in MAFLD. Recently, our group demonstrated that lupin protein hydrolysates (LPHs) had lipid lowering, antioxidant, and anti-inflammatory effects. Sixty male mice fed with a Western diet were intragastrically treated with LPHs (or vehicle) for 12 weeks. Liver and adipose tissue lipid accumulation and hepatic inflammatory and oxidant status were evaluated. A significant decrease in steatosis was observed in LPHs-treated mice, which presented a decreased gene expression of CD36 and LDL-R, crucial markers in MAFLD. In addition, LPHs increased the hepatic total antioxidant capacity and reduced the hepatic inflammatory status. Moreover, LPHs-treated mice showed a significant reduction in abdominal adiposity. This is the first study to show that the supplementation with LPHs markedly ameliorates the generation of the steatotic liver caused by the intake of a Western diet and reduces abdominal obesity in ApoE-/- mice. Future clinical trials should shed light on the effects of LPHs on MAFLD.
SN 2076-3921
YR 2021
FD 2021-07-29
LK https://hdl.handle.net/10668/27487
UL https://hdl.handle.net/10668/27487
LA en
DS RISalud
RD Apr 10, 2025